MeCure Industries Plc had its long-term issuer rating affirmed at BBB(NG) and short-term rating at A3(NG) by GCR Ratings, with the outlook revised to stable from positive.
The Lagos-based pharmaceutical company closed the first half of 2026 with improved earnings and market penetration, the firm said in a statement.
The rating agency cited MeCure’s stronger competitive position, sound earnings performance and ongoing expansion.
GCR pointed to product innovation and wider distribution as key drivers, noting the company’s portfolio of more than 140 formulations across five therapeutic classes.
Its extensive distribution network and relationships with suppliers and technical partners also supported the affirmation, the statement said.
MeCure closed H1 2026 on a strong note with two additional milestones: it secured Halal certification and launched two new products, expanding access to Muslim consumers and adding to its drug portfolio.
The moves come as Nigeria’s pharmaceutical firms invest in local manufacturing and import substitution to reduce dependence on foreign supply.
“For the everyday consumer, Halal certification means that the certified products have been reviewed to ensure that their ingredients, sourcing, handling, and production processes comply with recognised Halal requirements,” according to the statement.
It added that in practical terms, it gives Muslim consumers greater confidence that the medicines they use are permissible, while also providing an additional layer of assurance around transparency, product integrity, and manufacturing discipline.
The certification is expected to support trust among customers, healthcare professionals, distributors, and institutional partners, while strengthening MeCure’s positioning in markets where Halal-compliant products are an important consideration.
Also, in June 2026, the pharmaceutical company expanded its product portfolio with the introduction of Fluconazole Capsules and EBU Suspension.
Fluconazole Capsules add to the company’s antifungal offering, while EBU Suspension, an ibuprofen oral suspension, strengthens the firms paediatric and family care range.
The launches reflect the company’s continued focus on affordable, locally manufactured medicines across key therapeutic needs.
As the firm enters the second half of 2026, the company said it remains focused on deepening local manufacturing, improving access to quality medicines, expanding its product pipeline, and delivering sustainable value to shareholders.
Join BusinessDay whatsapp Channel, to stay up to date
Open In Whatsapp
